Your session is about to expire
← Back to Search
Other
A Study of LY3457263 in Obese Participants
Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose on day 1 up to 43 days postdose
Summary
This trial is testing a new drug called LY3457263 together with tirzepatide to see if they are safe and well-tolerated in overweight or obese people. The study will also measure how much of LY3457263 gets into the bloodstream and how long it stays in the body. The trial will last a few months.
Eligible Conditions
- Obesity
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ predose on day 1 up to 43 days postdose
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose on day 1 up to 43 days postdose
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Therapeutic procedure
Secondary study objectives
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3457263
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3457263 + TirzepatideExperimental Treatment2 Interventions
LY3457263 administered subcutaneously (SC) in combination with tirzepatide given SC.
Group II: Placebo + TirzepatidePlacebo Group2 Interventions
Placebo administered SC in combination with tirzepatide given SC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3457263
2022
Completed Phase 1
~200
Tirzepatide
2019
Completed Phase 3
~7520
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,679 Previous Clinical Trials
3,465,715 Total Patients Enrolled
69 Trials studying Obesity
46,523 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,389 Previous Clinical Trials
428,130 Total Patients Enrolled
51 Trials studying Obesity
25,296 Patients Enrolled for Obesity